Optimized Synthesis of Fmoc/Boc-Protected PNA Monomers and their Assembly into PNA Oligomers.
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Accepteret manuskript, 1,14 MB, PDF-dokument
Continuous advancement of application of peptide nucleic acid (PNA) oligomers encouraged exploration of rapid and efficient synthesis of PNA monomers and oligomers. Among the PNA monomers developed, only a few are commonly used in automated PNA synthesis. Herein, we report short and efficient protocols suitable for large-scale synthesis of Fmoc/Boc-protected PNA monomers with advantageous solubility properties; these also facilitate purification due to the traceless nature of the Boc protecting group. Initially, several coupling reagents were screened for assembly of a pentamer containing all four nucleobases, and then the most promising reagents were tested in the synthesis of a decamer. The Fmoc/Boc-protected monomers proved compatible with both manual synthesis and assembly on an automated peptide synthesizer at room temperature or at 40 °C. As compared to the commonly used coupling agent, 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (HATU), both 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and [ethyl cyano(hydroxyimino)acetato−O2]tri-1-pyrrolidinylphosphonium hexafluorophosphate (PyOxim) proved more favorable, with the latter being superior. A previously reported side reaction of guanine bases in the presence of benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) was not observed with the phosphonium salts.
Originalsprog | Engelsk |
---|---|
Tidsskrift | European Journal of Organic Chemistry |
Vol/bind | 2021 |
Udgave nummer | 19 |
Sider (fra-til) | 2792-2801 |
Antal sider | 10 |
ISSN | 1434-193X |
DOI | |
Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:
We would like to thank Birgitte Simonsen and Uraiwan N. Adamsen for practical assistance with compound purification and characterisation. Ashif Y. Shaikh was supported by a postdoctoral grant from the Center for Peptide‐Based Antibiotics (CEPAN) financed by the Novo Nordisk Foundation.
Funding Information:
We would like to thank Birgitte Simonsen and Uraiwan N. Adamsen for practical assistance with compound purification and characterisation. Ashif Y. Shaikh was supported by a postdoctoral grant from the Center for Peptide-Based Antibiotics (CEPAN) financed by the Novo Nordisk Foundation.
Publisher Copyright:
© 2021 Wiley-VCH GmbH
ID: 273132184